View ValuationCosmo 将来の成長Future 基準チェック /56Cosmo利益と収益がそれぞれ年間42.7%と26.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に13.5% 42.8%なると予測されています。主要情報42.7%収益成長率42.80%EPS成長率Pharmaceuticals 収益成長14.6%収益成長率26.7%将来の株主資本利益率13.48%アナリストカバレッジGood最終更新日01 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).お知らせ • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.お知らせ • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025お知らせ • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025お知らせ • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.お知らせ • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.お知らせ • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024お知らせ • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024お知らせ • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.お知らせ • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.業績と収益の成長予測OTCPK:CMOP.F - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028217589784512/31/2027179508470512/31/202610721216612/31/2025104-4-18-12N/A9/30/2025143282431N/A6/30/2025182606774N/A3/31/202522597112118N/A12/31/2024267133157162N/A9/30/202422696127130N/A6/30/2024185599897N/A3/31/2024139245860N/A12/31/202393-111823N/A9/30/20239902129N/A6/30/2023104112436N/A3/31/2023103142535N/A12/31/2022102172633N/A9/30/202290261724N/A6/30/20227835816N/A3/31/20227228614N/A12/31/20216522413N/A9/30/2021646816N/A6/30/202163-111219N/A3/31/202162-9816N/A12/31/202061-8513N/A9/30/202064-7-16N/A6/30/202067-7-80N/A3/31/202065-16-22-9N/A12/31/201962-24-36-19N/A9/30/201956-28N/A-17N/A6/30/201950-31N/A-15N/A3/31/201958-24N/A-12N/A12/31/201866-18N/A-10N/A9/30/201869-20N/A-10N/A6/30/201873-23N/A-11N/A3/31/201870-28N/A-10N/A12/31/201768-32N/A-9N/A9/30/201768-18N/A-6N/A6/30/201769-4N/A-2N/A3/31/2017698N/A10N/A12/31/20166819N/A22N/A9/30/20167018N/A18N/A6/30/20167216N/A14N/A3/31/201666132N/A-13N/A12/31/201561248N/A-39N/A9/30/201560241N/A-13N/A6/30/201559234N/A13N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CMOP.Fは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: CMOP.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: CMOP.F今後 3 年以内に収益を上げることが予想されます。収益対市場: CMOP.Fの収益 ( 26.7% ) US市場 ( 11.9% ) よりも速いペースで成長すると予測されています。高い収益成長: CMOP.Fの収益 ( 26.7% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CMOP.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 13.5 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/01 14:11終値2026/06/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cosmo N.V. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Estelle BétriseyBerenbergLaura HindleyBerenbergKerry HolfordBerenberg8 その他のアナリストを表示
お知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.
お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.
お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026
お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.
お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).
お知らせ • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.
お知らせ • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025
お知らせ • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
お知らせ • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.
お知らせ • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.
お知らせ • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024
お知らせ • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024
お知らせ • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.
お知らせ • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.